bucillamine + methotrexate + salazosulfapyridine

This is a triple combination therapy consisting of three disease-modifying antirheumatic drugs (DMARDs): bucillamine, methotrexate, and salazosulfapyridine (also known as sulfasalazine). This regimen is used primarily for the treatment of rheumatoid arthritis, particularly in patients who have not responded adequately to monotherapy or double DMARD therapy. The combination aims to provide an alternative to biologic therapies by leveraging the complementary mechanisms of action of each component: - **Methotrexate** acts as a folic acid antagonist, inhibiting dihydrofolate reductase and thus suppressing DNA synthesis in rapidly dividing cells such as immune cells. - **Bucillamine** is a thiol compound structurally related to D-penicillamine; it exerts anti-inflammatory effects by modulating immune responses and reducing oxidative stress. - **Salazosulfapyridine (sulfasalazine)** is metabolized into 5-aminosalicylic acid and sulfapyridine; it reduces inflammation through immunomodulatory effects. Clinical studies have shown that this triple DMARD combination can be as effective as TNF-inhibitor biologics in controlling disease activity and preventing joint damage in rheumatoid arthritis[1][5]. It provides an important non-biologic option for patients where biologics are contraindicated or not preferred.

Other names

bucillamine + methotrexate + sulfasalazine